Cycloproscaline

Cycloproscaline, also known as 4-cyclopropoxy-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline. It is the homologue of mescaline in which the 4-methoxy group has been replaced with a 4-cyclopropoxy group. The drug has a dose of 60mg or more orally and a duration of 6hours or more, but has not been fully evaluated. It is a low-potency full agonist of the serotonin 5-HT_2A receptor and also interacts with other serotonin receptors such as the serotonin 5-HT_1A and 5-HT_2C receptors. The drug's chemical synthesis has been described. Cycloproscaline was first described in the scientific literature by Daniel Trachsel and colleagues in 2013. Its pharmacology was studied in greater detail in 2021. The drug is not a controlled substance in Canada as of 2025.